查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1961414

二尖瓣疾病市場 - 全球產業規模、佔有率、趨勢、機會、預測：按治療類型、適應症、最終用戶、地區和競爭格局分類，2021-2031年

Mitral Valve Disease Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Treatment Type, By Indication, By End-User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球二尖瓣疾病市場預計將從 2025 年的 35.4 億美元成長到 2031 年的 58.9 億美元，複合年成長率達到 8.86%。

此領域涵蓋旨在修復或置換功能障礙的二尖瓣（尤其是狹窄和二尖瓣逆流等疾病）的醫療設備和手術介入措施。全球人口老化和結構性心臟疾病發病率上升是該領域的主要成長要素，從而催生了對持久性修復療法的強勁需求。此外，該行業正經歷著向微創經導管技術的明顯轉變，有效擴大了這些手術的適用患者群體。例如，胸腔外科醫師協會於2024年更新了其成人心血管手術資料庫，納入了針對退化性二尖瓣逆流的特定風險模型，這體現了此類治療的規模之大。這項更新得益於該協會管理的超過830萬份心血管手術記錄中記錄的大量病例。

市場概覽
預測期 2027-2031
市場規模：2025年 35.4億美元
市場規模：2031年 58.9億美元
複合年成長率：2026-2031年 8.86%
成長最快的細分市場 維修段
最大的市場 北美洲

儘管有這些有利趨勢，市場仍面臨許多挑戰，包括嚴格的法規環境以及開發下一代瓣膜系統所需的高昂成本。獲得衛生監管機構的核准需要全面的臨床證據，這可能會延長商業化進程，並阻礙中小企業進入市場。此外，不同醫療保健系統中複雜的報銷機制也對病患的就醫構成風險，尤其是對於昂貴的經導管器械而言，其保險覆蓋範圍可能存在限制。這些經濟因素可能會限制先進二尖瓣治療方法的普及，尤其是在醫療費用支出對成本較為敏感的地區。

市場促進因素

經導管二尖瓣治療技術的突破性進展正在改變整個產業，為高風險患者提供了一種有效的替代開胸手術的治療方案。經導管緣對緣修復術 (TEER) 和經導管二尖瓣置換術(TMVR) 等創新技術的引入，提高了手術的安全性和有效性，使其在臨床實踐中迅速普及。這一發展動能也體現在產業領導者的財務表現中。例如，愛德華生命科學公司在 2025 年第三季財報（2025 年 10 月）中揭露，其經導管主動脈瓣置換術術 (TMTT) 業務的銷售額年增 59.3%。同樣，雅培公司在 2024 年第四季及全年財報（2025 年 1 月）中顯示，其結構性心臟病業務的全球銷售額達到 22.5 億美元，這主要得益於其二尖瓣修復產品組合的強勁成長。

這些創新醫療設備的監管核准是市場成長的關鍵驅動力，使製造商能夠惠及更廣泛的患者群體，並將突破性治療方法商業化。 FDA等監管機構正擴大核准專為不適合傳統手術的患者設計的複雜系統。 FDA核准首個經房間隔穿刺主動脈瓣置換系統，並輔以可靠的臨床數據，這是一個重要的里程碑。正如2025年12月Fierce Biotech的報導《Edwards公司Sapien M3二尖瓣置換裝置獲FDA核准》中所報道，主要臨床試驗表明，約95%的受試者二尖瓣逆流症狀幾乎完全消失。這些監管核准凸顯了治療方法的安全性，並推動了全球投資和競爭。

市場挑戰

全球二尖瓣疾病市場受到嚴格的法規結構和開發新一代瓣膜系統所需高昂成本的嚴重限制。開發安全耐用的經導管裝置需要巨額資金來支持衛生當局要求的多階段臨床試驗。這種沉重的資金和時間負擔延緩了創新解決方案的推出，為中小型醫療技術公司設置了很高的進入門檻，從而降低了整體競爭。此外，高昂的研發成本導致最終產品價格高昂，這往往與注重成本控制的醫療保健系統嚴格的報銷政策相衝突，從而限制了患者獲得這些重要治療方法的機會。

因此，經濟限制和證據要件造成了瓶頸，阻礙了先進技術的充分利用。支付者越來越關注長期價值，並且對全面的臨床數據的需求日益成長，以證明保險覆蓋的合理性。 2024年，美國心臟學會發布了STS/ACC TVT註冊研究的最新結果，該研究分析了超過61,000例經導管緣對緣二尖瓣修復術。這些結果凸顯了患者群體的複雜性，並指出非心臟合併症仍然是術後死亡的主要原因。這些真實世界的臨床數據證明了監管機構嚴格審查的必要性，製造商必須克服這些審查，這進一步延長了產品核可到上市的時間。

市場趨勢

機器人輔助二尖瓣治療技術的快速發展和廣泛應用正在重塑外科領域，其高精度、微創的修復方式顯著降低了併發症並縮短了恢復時間。隨著外科醫生擴大利用微創機器人平台進行複雜的瓣膜重組，臨床療效已達到甚至超越傳統開胸手術的水平。這項技術革新正促使患者和醫療服務提供者廣泛接受機器人手術，使其成為新的治療標準。美國外科醫學會 (ACS) 於 2025 年 10 月發表的論文《心臟外科新時代：機器人整合》指出，一項針對 550 例全內視鏡機器人二尖瓣手術的研究顯示，術後 30 天的成功率高達 95.9%，證實了這些系統的安全性和有效性。

同時，人工智慧（AI）的整合應用正在提高診斷準確率和風險評估能力，以解決市場上診斷不足的問題。先進的AI演算法被應用於心臟超音波圖和心電圖，以檢測人工確認可能遺漏的二尖瓣逆流的細微生理徵兆。這些工具能夠根據患者的疾病進展風險進行分類，從而最佳化治療策略和長期療效，實現早期介入。 2025年7月，《心血管新聞》在報導中報道，研究人員利用一種新型AI增強型心電圖模型，成功識別出包括二尖瓣逆流在內的重大瓣膜性心臟病的風險，準確率達到69%至79%。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球二尖瓣疾病市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 治療方法（修復手術、置換術、心臟再同步治療、藥物治療）
    • 適應症（狹窄、脫垂、逆流）
    • 依最終使用者（醫院、門診手術中心等）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美二尖瓣疾病市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲二尖瓣疾病市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區二尖瓣疾病市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲二尖瓣疾病市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲二尖瓣疾病市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章 全球二尖瓣疾病市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Corcym UK Limited
  • Abbott Laboratories Inc
  • Zydus Lifesciences Limited
  • Medtronic plc
  • Edwards Lifesciences Corporation
  • Affluent Medical SA
  • ShockWave Medical, Inc.
  • Valcare Medical
  • Pfizer Inc
  • Teva Pharmaceutical Industries Ltd

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 17684

The Global Mitral Valve Disease Market is projected to expand from USD 3.54 Billion in 2025 to USD 5.89 Billion by 2031, achieving a CAGR of 8.86%. This sector encompasses medical devices and procedural interventions aimed at repairing or replacing dysfunctional mitral valves, specifically targeting conditions like stenosis and mitral regurgitation. Key growth factors include an aging global demographic and a rising incidence of structural heart defects, creating a strong demand for durable, restorative therapies. Moreover, the industry is seeing a distinct transition toward minimally invasive transcatheter technologies, which effectively broadens the eligible patient base. Highlighting the scale of these interventions, the Society of Thoracic Surgeons updated its Adult Cardiac Surgery Database in 2024 to incorporate specific risk models for degenerative mitral regurgitation, a change driven by the immense volume of procedures recorded in their registry of over 8.3 million cardiac operations.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 3.54 Billion
Market Size 2031USD 5.89 Billion
CAGR 2026-20318.86%
Fastest Growing SegmentRepair Segment
Largest MarketNorth America

Despite these favorable trends, the market contends with significant hurdles related to a stringent regulatory environment and the substantial costs involved in developing next-generation valve systems. Securing approval from health authorities necessitates comprehensive clinical evidence, a requirement that can prolong the path to commercialization and hinder market entry for smaller companies. Additionally, complex reimbursement frameworks within various healthcare systems pose a risk to patient access, as premium transcatheter devices may face coverage limitations. These economic factors potentially restrict the widespread adoption of advanced mitral valve therapies, particularly in regions where cost sensitivity governs healthcare spending.

Market Driver

Technological breakthroughs in transcatheter mitral valve therapies are transforming the industry by providing effective alternatives to open-heart surgery for high-risk patients. The introduction of innovations such as transcatheter edge-to-edge repair (TEER) and transcatheter mitral valve replacement (TMVR) has enhanced procedural safety and efficacy, driving rapid clinical uptake. This momentum is reflected in the financial results of major industry players; for instance, Edwards Lifesciences reported in their "Third Quarter 2025 Financial Results" (October 2025) that sales for their Transcatheter Mitral and Tricuspid Therapies (TMTT) unit surged by 59.3% year-over-year. Similarly, Abbott's "Fourth Quarter and Full-Year 2024 Financial Results" (January 2025) indicated that their Structural Heart division achieved global sales of $2.25 billion, a figure significantly bolstered by their mitral repair portfolio.

Regulatory approvals for these innovative devices act as a crucial engine for market growth, enabling manufacturers to reach wider patient groups and commercialize groundbreaking treatments. Authorities like the FDA are increasingly clearing complex systems designed for patients who are not suitable candidates for traditional surgery. A major milestone was reached when the FDA approved the first transseptal transcatheter mitral valve replacement system, backed by robust clinical data. As reported by Fierce Biotech in the December 2025 article "Edwards nets FDA approval for Sapien M3 mitral valve replacement," the pivotal trial demonstrated that approximately 95% of participants experienced near-complete elimination of mitral regurgitation. Such regulatory endorsements validate the safety of these therapies and encourage further investment and competition globally.

Market Challenge

The expansion of the Global Mitral Valve Disease Market is significantly hindered by a demanding regulatory framework and the exorbitant costs required to develop next-generation valve systems. Creating safe and durable transcatheter devices necessitates immense capital to fund the multi-phase clinical trials required by health authorities. This heavy financial and time burden slows the introduction of innovative solutions and establishes high barriers to entry for smaller medical technology companies, thereby reducing overall competition. Furthermore, the substantial development expenses lead to premium pricing for the final products, which often clashes with strict reimbursement policies in cost-conscious healthcare systems, ultimately restricting patient access to these critical therapies.

As a result, a bottleneck exists where advanced technologies remain underutilized due to economic constraints and evidentiary requirements. Payers are increasingly scrutinizing long-term value, intensifying the demand for comprehensive clinical data to justify coverage. In 2024, the American College of Cardiology highlighted updated findings from the STS/ACC TVT Registry, which analyzed over 61,000 mitral transcatheter edge-to-edge repair procedures. These findings emphasized the complexity of the patient population, noting that non-cardiac comorbidities remain a primary driver of post-procedural mortality. This real-world evidence validates the stringent scrutiny applied by regulators, which manufacturers must navigate, further extending the timeline for product approval and market adoption.

Market Trends

The rapid advancement and adoption of robotic-assisted mitral valve interventions are reshaping the surgical field by facilitating high-precision, minimally invasive repairs that reduce complications and recovery times. As surgeons increasingly utilize robotic platforms for complex valve reconstructions via small incisions, clinical outcomes are rivaling or surpassing those of traditional open-heart surgeries. This technological evolution is fostering broad acceptance among patients and healthcare providers, positioning robotic surgery as a rising standard of care. According to the American College of Surgeons' October 2025 article "Robotics Integration Ushers in New Era of Cardiac Surgery," a study of 550 totally endoscopic robotic mitral valve surgeries demonstrated a 30-day surgical success rate of 95.9%, confirming the safety and efficacy of these systems.

Concurrently, the integration of Artificial Intelligence (AI) for enhanced diagnostic precision and risk assessment is tackling the issue of underdiagnosis within the market. Advanced AI algorithms are being applied to echocardiograms and electrocardiograms to detect subtle physiological signs of mitral regurgitation that manual reviews might miss. These tools enable earlier intervention by categorizing patients based on disease progression risk, optimizing treatment strategies and long-term outcomes. In July 2025, Cardiovascular News reported in "AI model able to predict onset of valve regurgitation" that researchers successfully used a novel AI-enhanced electrocardiography model to identify the risk of developing significant valvular conditions, including mitral regurgitation, with an accuracy rate between 69% and 79%.

Key Market Players

  • Corcym UK Limited
  • Abbott Laboratories Inc
  • Zydus Lifesciences Limited
  • Medtronic plc
  • Edwards Lifesciences Corporation
  • Affluent Medical SA
  • ShockWave Medical, Inc.
  • Valcare Medical
  • Pfizer Inc
  • Teva Pharmaceutical Industries Ltd

Report Scope

In this report, the Global Mitral Valve Disease Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Mitral Valve Disease Market, By Treatment Type

  • Repair
  • Replacement
  • Cardiac Resynchronization Therapy
  • Therapeutics

Mitral Valve Disease Market, By Indication

  • Stenosis
  • Prolapse
  • Regurgitation

Mitral Valve Disease Market, By End-User

  • Hospitals
  • Ambulatory Surgical Centers
  • Others

Mitral Valve Disease Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Mitral Valve Disease Market.

Available Customizations:

Global Mitral Valve Disease Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Mitral Valve Disease Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Treatment Type (Repair, Replacement, Cardiac Resynchronization Therapy, Therapeutics)
    • 5.2.2. By Indication (Stenosis, Prolapse, Regurgitation)
    • 5.2.3. By End-User (Hospitals, Ambulatory Surgical Centers, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Mitral Valve Disease Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Treatment Type
    • 6.2.2. By Indication
    • 6.2.3. By End-User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Mitral Valve Disease Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Treatment Type
        • 6.3.1.2.2. By Indication
        • 6.3.1.2.3. By End-User
    • 6.3.2. Canada Mitral Valve Disease Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Treatment Type
        • 6.3.2.2.2. By Indication
        • 6.3.2.2.3. By End-User
    • 6.3.3. Mexico Mitral Valve Disease Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Treatment Type
        • 6.3.3.2.2. By Indication
        • 6.3.3.2.3. By End-User

7. Europe Mitral Valve Disease Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Treatment Type
    • 7.2.2. By Indication
    • 7.2.3. By End-User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Mitral Valve Disease Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Treatment Type
        • 7.3.1.2.2. By Indication
        • 7.3.1.2.3. By End-User
    • 7.3.2. France Mitral Valve Disease Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Treatment Type
        • 7.3.2.2.2. By Indication
        • 7.3.2.2.3. By End-User
    • 7.3.3. United Kingdom Mitral Valve Disease Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Treatment Type
        • 7.3.3.2.2. By Indication
        • 7.3.3.2.3. By End-User
    • 7.3.4. Italy Mitral Valve Disease Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Treatment Type
        • 7.3.4.2.2. By Indication
        • 7.3.4.2.3. By End-User
    • 7.3.5. Spain Mitral Valve Disease Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Treatment Type
        • 7.3.5.2.2. By Indication
        • 7.3.5.2.3. By End-User

8. Asia Pacific Mitral Valve Disease Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Treatment Type
    • 8.2.2. By Indication
    • 8.2.3. By End-User
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Mitral Valve Disease Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Treatment Type
        • 8.3.1.2.2. By Indication
        • 8.3.1.2.3. By End-User
    • 8.3.2. India Mitral Valve Disease Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Treatment Type
        • 8.3.2.2.2. By Indication
        • 8.3.2.2.3. By End-User
    • 8.3.3. Japan Mitral Valve Disease Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Treatment Type
        • 8.3.3.2.2. By Indication
        • 8.3.3.2.3. By End-User
    • 8.3.4. South Korea Mitral Valve Disease Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Treatment Type
        • 8.3.4.2.2. By Indication
        • 8.3.4.2.3. By End-User
    • 8.3.5. Australia Mitral Valve Disease Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Treatment Type
        • 8.3.5.2.2. By Indication
        • 8.3.5.2.3. By End-User

9. Middle East & Africa Mitral Valve Disease Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Treatment Type
    • 9.2.2. By Indication
    • 9.2.3. By End-User
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Mitral Valve Disease Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Treatment Type
        • 9.3.1.2.2. By Indication
        • 9.3.1.2.3. By End-User
    • 9.3.2. UAE Mitral Valve Disease Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Treatment Type
        • 9.3.2.2.2. By Indication
        • 9.3.2.2.3. By End-User
    • 9.3.3. South Africa Mitral Valve Disease Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Treatment Type
        • 9.3.3.2.2. By Indication
        • 9.3.3.2.3. By End-User

10. South America Mitral Valve Disease Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Treatment Type
    • 10.2.2. By Indication
    • 10.2.3. By End-User
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Mitral Valve Disease Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Treatment Type
        • 10.3.1.2.2. By Indication
        • 10.3.1.2.3. By End-User
    • 10.3.2. Colombia Mitral Valve Disease Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Treatment Type
        • 10.3.2.2.2. By Indication
        • 10.3.2.2.3. By End-User
    • 10.3.3. Argentina Mitral Valve Disease Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Treatment Type
        • 10.3.3.2.2. By Indication
        • 10.3.3.2.3. By End-User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Mitral Valve Disease Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Corcym UK Limited
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Abbott Laboratories Inc
  • 15.3. Zydus Lifesciences Limited
  • 15.4. Medtronic plc
  • 15.5. Edwards Lifesciences Corporation
  • 15.6. Affluent Medical SA
  • 15.7. ShockWave Medical, Inc.
  • 15.8. Valcare Medical
  • 15.9. Pfizer Inc
  • 15.10. Teva Pharmaceutical Industries Ltd

16. Strategic Recommendations

17. About Us & Disclaimer